BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirai Y, Saeki R, Song F, Koide H, Fukata N, Tomita K, Maeda N, Oku N, Asai T. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. International Journal of Pharmaceutics 2020;585:119479. [DOI: 10.1016/j.ijpharm.2020.119479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gupta U, Saren BN, Khaparkhuntikar K, Madan J, Singh PK. Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer. J Control Release 2022;348:1089-115. [PMID: 35640765 DOI: 10.1016/j.jconrel.2022.05.034] [Reference Citation Analysis]
2 Heshmati Aghda N, Dabbaghianamiri M, Tunnell JW, Betancourt T. Design of Smart Nanomedicines for Effective Cancer Treatment. Int J Pharm 2022;:121791. [PMID: 35525473 DOI: 10.1016/j.ijpharm.2022.121791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Gong G, Tang X, Zhang J, Liang X, Yang J, Li Q. Phenylboronic Acid-Modified Polyamidoamine Mediated the Transfection of Polo-Like Kinase-1 siRNA to Achieve an Anti-Tumor Efficacy. Int J Nanomedicine 2021;16:8037-48. [PMID: 34934312 DOI: 10.2147/IJN.S329433] [Reference Citation Analysis]
4 Hirai Y, Hirose H, Imanishi M, Asai T, Futaki S. Cytosolic protein delivery using pH-responsive, charge-reversible lipid nanoparticles. Sci Rep 2021;11:19896. [PMID: 34615928 DOI: 10.1038/s41598-021-99180-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Zhang Y, Sun C, Wang C, Jankovic KE, Dong Y. Lipids and Lipid Derivatives for RNA Delivery. Chem Rev 2021. [PMID: 34279087 DOI: 10.1021/acs.chemrev.1c00244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 36] [Article Influence: 1.0] [Reference Citation Analysis]
6 Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines (Basel) 2021;9:359. [PMID: 33918072 DOI: 10.3390/vaccines9040359] [Cited by in Crossref: 17] [Cited by in F6Publishing: 78] [Article Influence: 17.0] [Reference Citation Analysis]
7 Lu ZR, Laney VEA, Hall R, Ayat N. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy. Adv Healthc Mater 2021;10:e2001294. [PMID: 33615743 DOI: 10.1002/adhm.202001294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]